LLY · News · 20260912N

Competition and market share - weight-loss

ELI LILLY & Co · 2026-09-12 · Importance 17 · Surprise 24

Morgan Stanley expects Novo Nordisk to lose market share to Eli Lilly’s competing weight-loss offerings over the next 18 months. The commentary identifies Eli Lilly’s rival products as a competitive threat to Novo Nordisk in the obesity-treatment market, although it does not quantify Lilly’s current share or projected gains. The report also notes that Novo Nordisk’s semaglutide patent expirations in the early-to-mid 2030s could further affect its competitive position and sales exposure.